The Role of SNP rs2910164 in Patients Treated With Immune Checkpoint Inhibitors
NCT04038996 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 179
Last updated 2023-08-07
Summary
The objective of this study is to investigate whether the SNP rs2910164 in the pre-miR-146a gene is associated with outcome and toxicity of immune checkpoint inhibitor therapy.
Conditions
Sponsors & Collaborators
-
University of Freiburg
lead OTHER
Principal Investigators
-
Robert Zeiser, MD · University of Freiburg
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-07-31
- Primary Completion
- 2020-02-29
- Completion
- 2020-02-29
More Related Trials
-
Clinical Benefit of Genetic Biomarkers for Guiding Treatment Decisions in Oncology Drugs
NCT02458040 ·Status: WITHDRAWN
-
Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy
NCT05583422 ·Status: COMPLETED
-
Real-time Monitoring of Concentration and Size Variations of Circulating Plasma Free DNA to Predict Early Response to Immunotherapies in Patients With Different Types of Cancer.
NCT05083494 ·Status: UNKNOWN
-
Molecular Markers in Thyroid Cancer
NCT00598364 ·Status: COMPLETED
-
Identifying MSI Status From ctDNA in Chinese Patients With Refractory Advanced Solid Tumors
NCT03596593 ·Status: UNKNOWN ·Phase: NA
-
Study Investigating MEN1 and SDHD in Familial Carcinoid Tumors
NCT00672269 ·Status: UNKNOWN
-
An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
NCT05364086 ·Status: ACTIVE_NOT_RECRUITING
-
Biomarkers in Tumor Tissue Samples From Patients With Peripheral T-cell Lymphoma or Natural Killer Cell Neoplasms
NCT01390597 ·Status: COMPLETED
-
Validation of MMS Test for Cancer Monitoring
NCT02113683 ·Status: TERMINATED
-
Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study
NCT03707574 ·Status: COMPLETED
-
Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
NCT02243592 ·Status: ACTIVE_NOT_RECRUITING
-
Molecular Genetics Studies of Cancer Patients and Their Relatives
NCT04185935 ·Status: RECRUITING
-
Memory Phenotype and PD-1 Inhibition Response in Oral Cancer
NCT03862066 ·Status: TERMINATED
-
Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy
NCT01869218 ·Status: COMPLETED
-
Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
NCT06065592 ·Status: RECRUITING ·Phase: PHASE1
-
Utilization of Genomic Information to Augment Chemotherapy Decision-making for People With Incurable Malignancies
NCT01802905 ·Status: COMPLETED ·Phase: NA
-
SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)
NCT01402687 ·Status: COMPLETED
-
Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate
NCT01209299 ·Status: COMPLETED
-
Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment
NCT02105168 ·Status: UNKNOWN ·Phase: NA
-
Genetic Variants and Chemotherapy-induced Abnormal Thermal Sensation
NCT03252834 ·Status: TERMINATED
-
An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme)
NCT03955276 ·Status: TERMINATED
-
Evaluation of Autologous Natural Killer Cell Activity in Primary Cancer Cell Cultures
NCT05869994 ·Status: WITHDRAWN
-
Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions
NCT01457196 ·Status: COMPLETED ·Phase: NA
-
S9431: Studying Genes and Immune Response in Tumor Samples From Patients With Locally Advanced or Metastatic Melanoma
NCT00898183 ·Status: COMPLETED
-
PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcology
NCT05592665 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA